Search

Your search keyword '"Berger, KI"' showing total 125 results

Search Constraints

Start Over You searched for: Author "Berger, KI" Remove constraint Author: "Berger, KI"
125 results on '"Berger, KI"'

Search Results

1. Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.

3. PCR70 Avalglucosidase Alfa (AVA) Improves Symptoms and Functioning in Late-Onset Pompe Disease (LOPD) Patients vs Alglucosidase Alfa (ALG): Post-Hoc Analyses of Patient-Reported Outcomes (PROs) From COMET Trial

5. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

6. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start

7. International Guidelines for the Management and Treatment of Morquio A Syndrome

11. Case-control study of lung function in World Trade Center Health Registry area residents and workers.

14. Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers.

15. Obesity hypoventilation syndrome as a spectrum of respiratory disturbances during sleep.

16. Pompe disease: Unmet needs and emerging therapies.

17. Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.

18. Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.

19. Switching to e-cigarettes as harm reduction among individuals with chronic disease who currently smoke: Results of a pilot randomized controlled trial.

20. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.

21. Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease.

22. Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa.

23. Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.

24. Role of small airway dysfunction in unexplained exertional dyspnoea.

25. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.

26. Novel approach to studying effects of inhalational exposure on lung function in civilians exposed to the World Trade Center disaster.

27. Computer clinical decision support that automates personalized clinical care: a challenging but needed healthcare delivery strategy.

28. Molecular Clustering Analysis of Blood Biomarkers in World Trade Center Exposed Community Members with Persistent Lower Respiratory Symptoms.

29. COPD in Smoking and Non-Smoking Community Members Exposed to the World Trade Center Dust and Fumes.

30. Clinical significance and applications of oscillometry.

31. Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy.

32. Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial.

33. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.

34. Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions.

35. Validation of a Novel Compact System for the Measurement of Lung Volumes.

36. Respiratory impedance measured using impulse oscillometry in a healthy urban population.

38. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.

39. Increased Dead Space Ventilation and Refractory Hypercapnia in Patients With Coronavirus Disease 2019: A Potential Marker of Thrombosis in the Pulmonary Vasculature.

40. Characterization of Persistent Uncontrolled Asthma Symptoms in Community Members Exposed to World Trade Center Dust and Fumes.

41. Small airway function in obese individuals with self-reported asthma.

42. Technical standards for respiratory oscillometry.

43. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.

44. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

45. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.

46. Serum perfluoroalkyl substances and lung function in adolescents exposed to the World Trade Center disaster.

47. Bronchodilator Response Predicts Longitudinal Improvement in Small Airway Function in World Trade Center Dust Exposed Community Members.

48. Predictors of Asthma/COPD Overlap in FDNY Firefighters With World Trade Center Dust Exposure: A Longitudinal Study.

49. Respiratory Health and Lung Function in Children Exposed to the World Trade Center Disaster.

50. Obstructive Sleep Apnea in Community Members Exposed to World Trade Center Dust and Fumes.

Catalog

Books, media, physical & digital resources